Rituximab, which is approved for the treatment of some cancers and inflammatory conditions, also holds significant promise for patients with neurological diseases.
Rituximab, which is approved for the treatment of some cancers and inflammatory conditions, also holds significant promise for patients with neurological diseases.
Long-term rituximab use for the treatment of multiple sclerosis (MS) has been shown to be safe and well tolerated with recurrent administration, and a 2016 retrospective observational study published in Neurology found that patients with relapsing MS who were treated with rituximab could expect to experience 1 relapse every 23 years. The study’s authors suggested that further investigation of rituximab in patients with MS be given high priority for public funding, given the potential for patient benefit and reduction of high MS-related treatment costs. Rituximab has also been demonstrated to have long-lasting clinical benefits in patients with drug-resistant myasthenia gravis, and researchers have suggested that the drug be repurposed for this underserved patient population.
However, Roche, maker of the reference Rituxan/MabThera, has not sought regulatory approval for the drug’s use in neurology indications, perhaps because of its declining sales in the face of biosimilar competition. In the European Union, where biosimilars are already available, the reference biologic saw its sales decline by 16% last quarter.
As its hold on the rituximab market wanes, Roche has focused its efforts on its newer ocrelizumab (Ocrevus), a therapy much like rituximab, and one which carries a price tag of $65,000 per year. The drug maker gained FDA approval for the therapy in treating both relapsing and primary progressive MS in 2017, but news of ocrelizumab’s approval sparked controversy among clinicians. Annette Langer-Gould, MD, of the Los Angeles Medical Center and a former employee of Roche’s Genentech division, is quoted in Health News Review as saying that ocrelizumab is little more than an “expensive, overdosed version of Rituxan,” and a “fake breakthrough…it’s shameless.”
Roche appears to disagree; on Monday, the drug maker announced that it plans to present “the largest body of Ocrevus data presented at a congress to date” at the Seventh Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) later this month.
Patients with MS who hope for eventual relief from the high cost of treatment may still have some cause for optimism, however, as the market for biosimilar MS treatments appears to be heating up. Biotech companies Abzena and UGA Biopharma have announced the joint development of a cell line expressing a biosimilar to an existing treatment for MS. The company did not disclose the reference product, but said that the originator therapeutic earned $1.9 billion in sales in 2016.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.